Abstract Details

Title Disparities in Stroke Epidemiology between Two University Hospitals in Mexico and United States

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P05 - (-)

Poster/Presentation
Number 249

Objective

Background BACKGROUND: The general public's awareness of stroke symptoms can contribute significantly to seeking timely medical care. Stroke management includes intravenous thrombolysis that can improve disability at least 30% of cases at three months if given within 3 hours of symptom onset.

Design/Methods DESIGN/METHODS: This is a retrospective review comparing Hospital San Jose Tec de Monterrey (HSJ) in Monterrey, Mexico and University of Colorado Hospital (UCH) in Denver, Colorado USA. 328 charts were reviewed from January to December 2011. Data obtained included the annual incidence of CVD, time of symptom onset to hospital arrival, type of patient transportation, EMS advance notification, frequency of intravenous thrombolytic therapy and time from hospital arrival to its administration.

Results RESULTS: UCH had 276 CVD cases with 141 acute ischemic strokes (AIS). Of those, 25 patients were treated with thrombolytic therapy (17.73%). HSJ had 52 patients of CVD with 34 cases of AIS. 4 patients were treated with thrombolytic therapy (11.76%). At UCH, 111 patients (40.21%) arrived by EMS and 83 (30.04%) by private car or taxi, while at HSJ, 18 patients (34.61%) arrived by EMS and 29 (55.76%) by private car or taxi. Advance notification by EMS was given in 33 cases (33.67%) at UCH and 5 cases (27.77%) at HSJ. At HSJ, 25 patients (48.07%) arrived more than 6 hours after symptom onset; while 68 patients (24.63%) did at UCH. Thrombolytic was administered before 90 minutes in 23 patients (90.46%) at UCH compared to 2 patients (50%) at HSJ.

Conclusions CONCLUSIONS: The lower CVD cases, thrombolytic therapy administration, EMS advance notification and prolonged arrival time after symptom onset suggest a possible deficit of stroke awareness, urgency and a stroke alert system in Monterrey, Mexico.

Authors/Disclosures
Mario A. Cerdan-Trevino, MD, FAAN (NeuroDoctors) PRESENTER	No disclosure on file
Leonel Cantu-Martinez, MD	Dr. Cantu-Martinez has nothing to disclose.
Angel A. Pulido, MD (Rio Grande NeuroScience)	No disclosure on file
	No disclosure on file
Hector R. Martinez, MD (Instituto de Neurología y Neurocirugía Hospital Zambrano Hellion)	Dr. Martinez has nothing to disclose.
William J. Jones, MD (University of Colorado Denver School of Medicine)	Dr. Jones has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Childs McCune Attorneys. The institution of Dr. Jones has received research support from PCORI.
	No disclosure on file

��ɫ��

��ɫ��